Back to directory
Investor
Sectoral Asset Management
Montréal, QC, Canada
The 50 · Series B+ · Life Sciences
Privately held emerging life science companies developing innovative medical treatments based on disruptive technologies. North America and Europe focus on biotechnology and medical technology. High velocity characteristics.
- Type
- The 50
- Stage
- Series B+
- AUM
- US$392M
- Other offices
- Geneva · Hong Kong
- Source
- The 50: Canadian VC Ecosystem Guide 2026
Investment thesis
Privately held emerging life science companies developing innovative medical treatments based on disruptive technologies. North America and Europe focus on biotechnology and medical technology. High velocity characteristics.
What makes them unique
Global sourcing with investment personnel in North America and Europe. Extensive public side experience enabling IPOs and M&A transactions.
Team
- 9 professionals, 5 partners, 3 principals with scientific, financial and company expertise
Select portfolio
AMOLYT (acquired by AstraZeneca for $1B - 3.3x)LENZ (IPO)MINERALIS (IPO)